Researchers have determined the prognostic impact of fibrinogen/albumin ratio in esophageal squamous cell carcinoma patients.
One of the most common malignancy worldwide is Esophageal cancer. The major type of this malignancy is the esophageal squamous cell carcinoma (ESCC). In recent years research has indicated that neoadjuvant chemoradiotherapy may be more appropriate for locally advanced esophageal cancer while surgery is the main treatment strategy for early stage disease. However, lack of a diagnostic biomarker makes it difficult for clinicians to determine the treatment strategy accurately depending on preoperative staging.
It is widely known that coagulation and nutrition play important roles in cancer progression. Previous studies have indicated that elevated preoperative fibrinogen level might induce higher malignancy progression and poor prognosis. In addition, it has been demonstrated that malnutrition is a predictor in various cancers, and albumin is regarded as a nutritional indicator. Hence, a new study looked at fibrinogen/albumin ratio (FAR) and its prognostic impact in ESCC patients.
In a study led by Dr. Jianhua Fu, investigators retrospectively analyzed 1135 patients with radical esophagectomy for ESCC from January 2008 to December 2010 at the State Key Laboratory of Oncology in South China. Researchers found that preoperative FAR was an independent prognostic factor in ESCC patients and that lower FAR could improve overall survival of these patients.
However, this study was limited to its retrospective design including data collection. The data were from a single centre and whether these findings can be applicable to other centres needs to be validated.